ad

Pfizer Q4 Results 2025 Declared 85% Rise in Profit and 8.3% Surge in Revenue: Check Key Highlights

21 May 20251:00 pm

Pfizer Q4 Results 2025 Declared 85% Rise in Profit and 8.3% Surge in Revenue: Check Key Highlights

Pfizer has reported its Q4 results for FY25 with a robust surge in profit by 85% YoY. Following the rise in profitability. Pfizer India share price surged 10% yesterday on 20th May 2025. Investors are cautious about next trigger of Pfizer India share price and market reactions to its Q4 results for FY25. 

Pfizer India Q4 Results 2025: Key Highlights

  • Pfizer India reported its revenue surge by 8.3% YoY to reach ₹591.90 crore in the Q4FY25.
  • Pfizer declares a strong growth of 85% YoY in the net profit, reaching ₹331 crore against ₹179 crore. 
  • EBITDA of Pfizer India is estimated at ₹227.50 crore with a 20.10% YoY increase from the previous EBITDA.
  • The EBITDA margin of Pfizer India improved to 38.40% from 34.70% in the Q4FY24.  

Pfizer India Share Dividend Declaration

The board of directors at Pfizer India has recommended a total dividend of ₹165 per share for the FY25. This dividend amount includes a final dividend of ₹35 per share and a special dividend of ₹100 per share to commemorate the company’s 75th year in India. Moreover, additional ₹30 per share arising from gains on the transfer of leasehold land and building. The record date for Pfizer India dividend is prescribed as 9th July 2025. 

Pfizer India Share Performance

Pfizer India share price is currently trading at ₹4,899.60 per share, tumbling over 1.01% or ₹49.80 on 21st May 2025. The stock has delivered 17.26% returns in the past 5 years and 0.71% of Dividend Yield last year. The 52-week high/low of Pfizer India shares is ₹6,451.15/₹3,701.00. 

Final Thoughts

Pfizer India declared an 8.3% revenue surge and an 85% profit rise YoY in its Q4 2025 results. The company's board of directors has recommended a total dividend of ₹165 per share for the FY25. This dividend amount includes a final dividend of ₹35 per share and a special dividend of ₹100 per share to commemorate the company’s 75th year in India. Investors have high confidence in Pfizer India shares for the long term and are waiting for new positive triggers in the shares. 

For regular stock updates, dividend alerts, and expert verdicts, stay informed with Univest!

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities. 

Recent News Articles

Stock Market Today: Sensex Soar 119 Points & Nifty50 By 0.09%; Check Key Insights

Hindalco Q4 Results 2025 Declared 66% Rise in Profit and 16% Surge in Revenue: Check Key Highlights

Stocks to Watch Today: 21st May 2025 | Dixon, GSFC, United Spirits, IRCON, Zaggle, & More!

Zydus Lifesciences Q4 Results 2025 Declared 1% Dip in Profit and Dividend of ₹11 Per Share: Check Key Highlights

Victory Electric IPO GMP: Day 1 IPO Live Updates

BEL Q4 Results 2025: Q4 PAT Jumps 18.4% to ₹2,127.02 crores. Dividend Declared @ 0.90 per share.

Stock Market Today: Sensex Fell 152 Points & Nifty50 By 0.19%; Check Key Insights

Stocks to Watch Today: 20th May 2025 | NLC India, Hindustan Foods, DOMS, Kwality Pharmaceuticals, ACME, & More!

Other News Articles

BEL Q4 Results 2025: Q4 PAT Jumps 18.4% to ₹2,127.02 crores. Dividend Declared @ 0.90 per share.

Victory Electric Vehicles IPO GMP & Review: Apply or Avoid?

Data Patterns Q4 Results 2025: Q4 Netprofit Shoots Up By 60% YoY and Revenue Rises 117.35%.

Divi’s Lab Q4 Results 2025: Q4 FY25 PAT grows 23% and Revenue Zooms to ₹2,585 crores; ₹30/share Dividend Declared

Delhivery Q4 Results 2025 | Q4 FY25 PAT at ₹72.56 Cr; Revenue Rises 5.6% Y-o-Y.

List of Small-Cap Stocks in NSE for 2025

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5
ad

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited

Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003

Write to us : support@univest.in, compliance@univest.in

Verify on SEBI registry →

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down